<DOC>
	<DOCNO>NCT00477490</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety several dos melt formulation desmopressin broad population adult patient nocturia .</brief_summary>
	<brief_title>Efficacy Safety Desmopressin Melt Treatment Nocturia</brief_title>
	<detailed_description />
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Inclusion Criteria 1 . Written inform consent prior performance studyrelated activity . 2 . Patients 18 year old average â‰¥ 2 nocturnal void per night determine 3 day frequencyvolume chart screen period . Males : 1 . Clinical suspicion bladder outlet obstruction and/or urine flow &lt; 5 ml/s . If medical history and/or physical examination suggest bladder outlet obstruction , uroflowmetry perform confirm diagnosis 2 . Surgical treatment bladder outlet obstruction/benign prostatic hyperplasia perform within past 6 month Females : 3 . Pregnancy . Females reproductive age must documentation reliable method contraception . 4 . Use pessary pelvic prolapse . 5 . Unexplained pelvic mass . Males Females : 6 . Clinical suspicion urinary retention and/or post void residual volume &gt; 150 ml . If medical history and/or physical examination suggest urinary retention , bladder ultrasound catheterization perform confirm diagnosis . 7 . Current past urologic malignancy ( e.g. , bladder cancer , prostate cancer ) . 8 . Clinical evidence current genitourinary tract pathology could interfere void . 9 . History neurogenic detrusor activity ( previously know detrusor hyperreflexia ) . 10 . Suspicion evidence cardiac failure . 11 . Uncontrolled hypertension . 12 . Uncontrolled diabetes mellitus . 13 . Renal insufficiency . Serum creatinine must within normal limit estimate glomerular filtration rate ( eGFR ) &gt; =60 mL/min . 14 . Active hepatic and/or biliary disease . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2 time upper limit normal . Total bilirubin &gt; 1.5 mg/dL . 15 . Hyponatremia . Serum sodium level must within normal limit 16 . Syndrome Inappropriate antidiuretic hormone secretion ( SIADH ) . 17 . Diabetes insipidus ( urine output &gt; 40 ml/kg 24 hour ) determine 3day void diary . 18 . Psychogenic habitual polydipsia 19 . Obstructive sleep apnea Other 20 . Known alcohol substance abuse 21 . Work lifestyle potentially interfere regular nighttime sleep ( e.g. , shift worker ) 22 . Previous desmopressin treatment nocturia . 23 . Any medical condition , laboratory abnormality , psychiatric condition , mental incapacity language barrier , judgment investigator , could impair patient participation trial . 24 . Use loop diuretic ( furosemide , torsemide , ethacrynic acid ) . Other class diuretic ( thiazide , triamterene , chlorthalidone , amiloride , indapamide ) permit , either monotherapy combination therapy . Subjects use diuretic encouraged take morning , medically feasible . 25 . Use investigational drug within 30 day screen . Concomitant Medications The following medication permit provided subject stable dose 3 month prior screen date ( i.e . treatment initiated discontinue change dose ) : Alphablockers : Cardura ( doxazosin ) ; Flomax ( tamsulosin ) ; Hytrin ( terazosin ) ; Uroxatral ( alfuzosin ) 5 alphareductase inhibitor : Avodart ( dutasteride ) ; Proscar ( finasteride ) Antispasmodic , anticholinergic , antimuscarinic therapy overactive bladder : Detrol , Detrol LA ( tolterodine ) ; Ditropan , Ditropan XL ( oxybutynin ) ; Enablex ( darifenacin ) ; Levsin ( hyoscyamine ) ; Oxytrol transdermal ( oxybutynin ) ; Sanctura ( trospium ) ; Vesicare ( solifenacin ) Sedative/hypnotic medication sleep disorder Selective serotonin mixed norepinephrine/serotonin reuptake inhibitor : Celexa ( citalopram ) ; Cymbalta ( duloxetine ) ; Effexor ( venlafaxine ) ; Lexapro ( escitalopram ) ; Paxil ( paroxetine ) ; Prozac ( fluoxetine ) ; Zoloft ( sertraline ) Chronic use nonsteroidal antiinflammatory agent Diabinese ( chlorpropamide ) Carbamazepine ( carbatrol/tegretol ) Amiodarone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>